DrugDashboards

Sodium Chloride

Sodium Chloride · SODIUM CHLORIDE 9 mg/mL · Injection · Intramuscular; Intravenous; Subcutaneous · Hikma Pharmaceuticals USA Inc.

NDC 00641-6144-25 · 25 VIAL in 1 CARTON / 10 mL in 1 VIAL · ANDA · View full market →

The short version

11 companies supply this market — deep enough that no single failure threatens the supply. Historically, drugs in this position went on to a new shortage within 90 days about 1.5% of the time — roughly 10× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

1.5%chance of a new FDA shortage posting for sodium chloride (injectable) in the next 90 days

sterile injectable · 13 Class I/II recall(s) in 12 months · OAI inspection at a producing facility (24 months)

For scale: the typical drug’s chance is about 0.1% — this one is 10× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $16.68 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA201833
TE code
AP
Approval date
Sep 24, 2013
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class II · TerminatedDec 7, 2020
    Hikma Pharmaceuticals USA Inc. — Failed pH Specifications: Out of Specification pH Test Results were found in Sodium Chloride Injection USP 0.9% 2ml vial.
  • Class II · TerminatedNov 3, 2020
    Hikma Pharmaceuticals USA Inc. — Failed pH Specifications: Out of Specification pH Test Results were found in Sodium Chloride Injection USP 0.9% 2 mL vial.

Manufacturers of Sodium Chloride (Injection)

LabelerStrengthFirst seenLast seen
Baxter Healthcare CorporationSODIUM CHLORIDE 450 mg/100mLJul 15, 2026Sep 3, 2026
Baxter Healthcare CorporationSODIUM CHLORIDE 450 mg/50mLJul 15, 2026Sep 3, 2026
Baxter Healthcare CorporationSODIUM CHLORIDE 900 mg/100mLJul 15, 2026Sep 3, 2026
B. Braun Medical Inc.SODIUM CHLORIDE 9 mg/mLJul 15, 2026Sep 2, 2026
Cardinal Health 107, LLCSODIUM CHLORIDE 9 mg/mLJul 15, 2026Sep 2, 2026
Fresenius Medical Care de Mexico, S.A. de C.V.SODIUM CHLORIDE 900 mg/100mLJul 15, 2026Sep 2, 2026
Fresenius Medical Care Renal Therapies Group, LLCSODIUM CHLORIDE 900 mg/100mLJul 15, 2026Sep 2, 2026
Henry Schein, Inc.SODIUM CHLORIDE 9 mg/mLJul 15, 2026Sep 2, 2026
Liebel-Flarsheim Company LLCSODIUM CHLORIDE .9 mg/mLJul 15, 2026Sep 2, 2026
Nephron Pharmaceuticals CorporationSODIUM CHLORIDE 9 mg/mLJul 15, 2026Sep 2, 2026
Sanofi Vaccines US Inc.SODIUM CHLORIDE 4.5 mg/.5mLJul 15, 2026Sep 2, 2026
Fresenius Kabi USA, LLCSODIUM CHLORIDE 9 mg/mLJul 15, 2026Aug 31, 2026
Hikma Pharmaceuticals USA Inc.SODIUM CHLORIDE 9 mg/mLJul 15, 2026Aug 28, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Sodium Chloride — NDC 00641-6144-25," retrieved September 3, 2026, https://drugdashboards.com/drug/00641614425.

Free to cite with attribution — see how the data is put together.